Form PTO-1449 (REV. 8-83)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053

In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

NOV 0 2 2000 B

Applicant: Bachovchin

Filing Date: April 9, 1999 Group: 1653

U. S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
X	* 4,318,904	Shaw et al.	March 9, 1982	424	177
X	* 4,443,609	Oude Alink et al.	April 17, 1984	548	111
X	* 4,499,082	Shenvi et al.	February 12, 1985	514	2
X	* 4,582,821	Kettner et al.	April 15, 1986	514	18
X	* 4,636,492	Kettner et al.	January 13, 1987	514	18
X	* 4,644,055	Kettner et al.	February 17, 1987	530	330
X	* 4,652,552	Kettner et al.	March 24, 1987	514	18
X	* 4,935,493	Bachovchin et al.	June 19, 1990	530	331
X	* 4,963,655	Kinder et al.	October 16, 1990	530	331
X	* 5,093,477	Mölling et al.	March 3, 1992	530	328
X	* 5,187,157	Kettner et al.	February 16, 1993	514	18
X	* 5,215,926	Etchells, III et al.	June 1, 1993	436	501
X	* 5,242,904	Kettner et al.	September 7, 1993	514	18
	* 5,250,720	Kettner et al.	October 5, 1993	558	288
X	* 5,288,707	Metternich	February 22, 1994	514	19
X	* 5,296,604	Hanko et al.	March 22, 1994	546	169
X	* 5,329,028	Ashkenazi et al.	July 12, 1994	548	548
X	* 5,378,624	Berenson et al.	January 3, 1995	435	239
X	* 5,384,410	Kettner et al.	January 24, 1995	548	405
1/	* 5,444,049	de Nanteuil et al.	August 22, 1995	514	18
X	* 5,462,928	Bachovchin et al.	October 31, 1995	514	19

Form PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		Atty. Docket: 2002941-0053	In re App 09/289,3	olication No. 21	
INFORMATION DISCLOSURE STATEMENT NOV 0 2 2000			Applicant: Bachovchin		
(Use several sheets if necessary)		Filing Date: April 9, 1999	Group: 1653		
	* 5,506,130	Peterson et al.	April 9, 1996	435	240.1
X	* 5,527,923	Klinger et al.	June 18, 1996	548	570
1	* 5,543,396	Powers et al.	August 6, 1996	514	19
X	* 5,554,728	Basava et al.	September 10, 1996	530	327
4	* 5,635,386	Palsson et al.	June 3, 1997	435	372
1	* 5,635,387	Fei et al.	June 3, 1997	435	378
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	* 5,646,043	Emerson et al.	July 8, 1997	435	373

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
X	.DD158109	Germany	29 December 1982		X
X	DD270382A1	Germany	26 Jul y 1989		X
X	DD296075A5	Germany	21 November 1991		X
- XX .	EP 0356223A2	Europe	28 February 1990	X	
-X	EP 0371467A2	Europe	6 June 1990		X
X	* EP 0420913B1	- Europe	15 November 1995		
X	*EP 0471651A2	Europe	19 February 1992		
	EP 0481311A2	Europe	> 22 April 1992		X
$\overline{}$	EP-0615978A1	Europe	21 September 1994		X
$\overline{}$	EP 0688788A1	Europe	27 December 1995		X
1 X	* WO 89/03223	PCT	20 April 1989		
\ \ \ \	* WO 91/16339	PCT >	31 October 1991		
X	* WO 91/17767	PCT	28 November 1991		

E DTO 1440	IIC Dance	tment of Commerce	Atty. Docket:	In re Application No.
Form PTO-1449 (REV. 8-83)		Trademark Office	2002941-0053	09/289,321
	ORMATION URE STATEMENT	OIPE	Applicant: Bachovchi	n
(Use seve	ral sheets if necessary)	NOV 0 2 2000 PCT	Filing Date: April 9, 1999	Group: 1653
<u> </u>	* WO 92/12140	PCT	23 July 1992	
X	* WO 92/17490	PCT	15 October 1992	
X	* WO 93/02057	PCT	4 February 1993	
/	* WO 93/05011	PCT	18 March 1993	
1	* WO 93/08259	PGT	29 April 1993	
X	* WO 93/10127	Pet	27 May 1993	
1	* WO 93/16102	PCT	19 August 1993	
1	* WO 94/03085	PCT	17 February 1994	
1	* WO 94/09132	PCT	28 April 1994	
X	* X/O 94/20526 ·	PCT	15 September 1994	
7	* WO 94/25873 :/A	PCT	10 November 1994	
X =	* WO 94/28915 V-	PCT	22 December 1994	
1	* WO 94/29335 . V_	PCT	22 December 1994	
7 =	* WO95/11689 , ./_	PCT	4 May 1995	
/ / /	WO95/15309	PCT	6 June 1995	X
	* WO 95/15309	PCT	8 June 1995	
	* WO 95/12618 · V=	PCT	11 May 1995	
/ <u>\</u>	* WO 95/29190 . 🗸	PCT	2 November 1995	
	* WO 95/29691	-PCT	9 November 1995	
\\\ \\ \\ \\ \\ \	* WO 95/34538 · ,	PCT	21 December 1995	
X X-	* WO 96/40858 . V	P CT	19 December 1996	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	* WO 96/40263	PCT	19 December 1996	
DP	WO 98/00439	PCT	8 January 1998	X
F)F	WO 98/50046 .	PCT	12 November 1998	X
De la companya della companya della companya de la companya della	WO 98/50066 · V	PCT	12 November 1998	X

;

					¬
Form PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321		
INFORMATION DISCLOSURE STATEMENT		Applicant: Bachovchin			
(Use seve	ral sheets if necessary)	NOV 0 2 2000	Filing Date: April 9, 1999	Group: 1653	
SL	WO 99/16864	PCT	8 April 1999	X	
Examiner's Initials	OTHER DOCUMEN (Including Author, Ti	TS tle, Date, Pertinent Pa	ges, Etc.)		
DL	Immun. Rev., 157:13-4				
X	* Austin, D.J., et al., "I Dimerization in Biolog	Proximity Versus Allostogy", <i>Chemistry & Biolog</i>	ery; The Role of Regulary, 1:131-136, (1994)		V
X	* Bachovchin, W.W., et al., "Inhibition Of IGA 1 Proteinases From Neisseria Gonorrhoeae And Hemophikus Influenzae By Peptide Prolyl Boronic Acids", J. Biol. Chem., 265:3738-3743-(1990).				
X	* Bailey, P.D., "An Introduction To Peptide Chemistry", Wiley Publishers, 1-81, (1990) * Barton, R.W.J., et al., "Binding Of The T Cell Activation Monocional Antibody Tal To Dipeptidyl Peptidase IV", J. Leukocyte Biology, 48:291-296 (1990).				
DX	Baugh, R., et al., "Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction", <i>Proteinases And Tumor Invation</i> , 165 :157-180 (1980).				
	* Blumenstein, et al., "Synthetic Non-Peptide Inhibitors of HIV Protease" Biochemical and Biophysical Research Communications 163(2): 980-87, 1989. * Bodanszky, M., "Principles Of Peptide Synthesis", Springer-Verlag, 16: (1984)				_
		Practice Of Peptide Synth	<u>. </u>	V	$\frac{1}{2}$
$\overline{}$		ide Chemistry, A Practic	``	`\	
X	Conformations", Tetra	Fluoroolefin Peptide Isos hedron Letters, 35:6033	3-6036., (1994)		
1	/* Brady, L., and Dodson, G., "Reflections On A Peptide", Nature, 368:692-693/(1994) (* Brander, et al., "Heterogeneous T Cell Responses to B-Lactam-Modified Self-Structures Are Observed in Penicillin-Allergic Individuals" J. Immunol. 155 (5):2670-2678 (1995).				
	* Brenchley, et al., "Towards Defining Antigens in Human Membranous Nephropathy" Nephrology, Dialysis, Transplantation 7 Supp. 1: 21-24, (1992). Bristol, L.A., et al., "Characterization Of A Novel Rat Thymocyte Costimulating Antigen By				<i>'</i> -
	The Monoclonal Antib	naracterization Of A No ody 1.3", <i>J. Immunol.</i> , T Thymocyte Costimulation	148:332-338 (1992).		1
X	Co-stimulation Of Gran Immunol., 149:367-372	nulocyte, Macrophage, 7 2 (1992).	Lineage Cell Prolifera	tion Via CD26," J.	
DL		on of CD26 Enzyme Acge Colony Formation at 509, 1995.			-

;

U.S. Department of Commerce Atty. Docket: In re Application No. Form PTO-1449 2002941-0053 09/289,321 (REV. 8-83) Patent and Trademark Office **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) 1653 April 9, 1999 * Bungy, et al., "Mapping of Tell Epitopes of the Major Fraction of Rye Grass Using Peripheral Blood Mononuclear Cells From Atopics and Non-Atopics. II. Isoallergen Clone 5A of Lolium Perenne Group I (Lol p I). Eur. J. Immunol. 24 (9):2098-2103 (1994). * Chan, et al., "Archives of Ophthalmology 113 (5):597-600 (1995). * Chazenblak, et al., "Human Organ-Specific Autoimmune Disease", Molecular Cloning and Expression of an Autoantibody Gene Repertoire For a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ, J. Clinical Investigation 92 (1):62-74 (1993). * Colowick, S., et al., "Methods In Enzymology", Pp. 220-225. * Cordes, E., et al., "Transition States For Hydrolysis Of Acetals, Ketals Glycosides, And Glycosylamines", Chapter 11, Pp. 429-465 * Coutts, et al., "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. V. Variation of the P₂ Position of X_{aa} -boroPro Dipeptides", J. Med. Chem., 39: 2087-94, 1996. * Dang, N.H., et al., "Cell Surface Modulation of CD26 By Anti-1F7 Monocional Antibody: Analysis Of Surface Expression And Human T Cell Activation", J. Immunol., 145:3963-3971 (1990)/. * Darcy, et al., "Protection of Mice and Nude Rats Against Toxolasmosis by A Multiple Aptigenic Peptide Construction Derived From Toxoplasma Gondii P30 Antigen", J. Immunol. **1/49** (11):3636-3641 (1992). * Darmoul, D., et al. "Dipeptidyl Peptidase IV (CD26) Gene Expression in Enterocyte-like Colon Cancer Cell Lines HT-29 And Caco-2; Cloning Of The Complete Human Coding Sequence And Changes of Dipeptidyl Peptidase IV mRNA Levels During Cell Differentiation," J. Biological Chemistry, 267:220-2208 (1992). * Daw, et al. "Glutamic Acid Decarboxy ase Autoantibodies in Stiff-Man Syndrome and Insulin-Dependent Diabetes Mellitus Exhibit Similarities and Differences in Epitope Recognition", J. Immunol. 156 (2): \$18-825 (1996). * De Caestecker, M.P., et al., "The Detection Of Intercytoplasmic Interleukin 1 (Alpha) Expression In Human Monocytes Using Two Colour Immunofluorescence Flow Cytometry", J. Immunol. Methods 154:11-20 (1992). *Demuth, H.U., et al. "Design Of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides As Potent Inhibitors Of Proline-Specific Peptidases", FEBS Lett., 320:23-* Dudler, et al., "Carbohydrate-Dependent, HLA Class II-Restricted, Human T Cell Response to the Bee Venom Allergen Phospholipase A2 in Allergic Patients", Eur. J. Immunol. 25 * Duke-Cohan, J.S., et al., "Targeting Of An Activated T-Cell Subset Using A Bispecific Antibody-Toxin Conjugated Directed Against CD4 AND CD26", Blood, 82:2224-2234., (1993).

In re Application No. Form PTO-1449 U.S. Department of Commerce Atty. Docket: Patent and Trademark Office 2002941-0053 09/289,321 (REV. 8-83) **INFORMATION** Applicant: Bachovchin **DISCLOSURE STATEMENT** NOV 0 2 2000 Filing Date: Group: (Use several sheets if necessary) April 9, 1999 1653 Dupont, B., "Immunology Of Hematopoietic Stem Cell Transplantation: A Brief Review Of Its History", Immun. Rev., 157:5-12. (1997) * Ebenbichler, C., et al., "Structure-function Relationships Of The HIV-1 Envelope V3 Loop Tropism Determinant: Evidence For Two Distinct Conformations", Aids 7:639-46 (1993). * El Far, et al., "Antigens Associated with N- and L-Type Calcium Channels in Lambert -Katon Myasthenic Syndrome", J. Neurochemistry, 64 (4): 1696-1702 (1995). * Kauci, A.S., "The Human Immunodeficiency Virus: Infectivity And Mechanisms Of Pathogenesis", Science, 239:617:722 (1988). * Fleisher, B., et al., "Triggering of Cytotoxic T Lymphocytes and NK Cells Via The Tp 103 Pathway is Dependent On the Expression Of The T Cell Receptor/CD3 Complex", J. *Immuno,,* \141:1103-1107. * Flentke, O.R., et al., "Inhibition Of Dipeptidyl Aminopeptidase IV (DP-IV) By XAA-Boropro Dipetides And Use Of These Inhibitors To Examine The Role Of DP-IV IN T-Cell Function", Proc. Natl. Acad. Sci. USA, 88:1556-1559, (1991) * Freeman, et al., "T and B Cell Reactivity to Adrenal Antigens in Autoimmune Addison's Disease" Clinical & Experimental Immunology 88 (2): 275-279 (1992) Goodman, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls", Annals of the Rheumatic Diseases, 55: 40-* Goodman, M., and Chorev, M., "On The Concept Of Linear Modified Retro-Peptide Structures", Accounts of Chemical Research, 12:1-7 (1979) Goodstone, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls" Annals Of The Rheumatic Diseases 55(N:40-46(1996). * Guichard, G. et al. "Partially Modified Retro-Inverso Pseudopeptides As Non-Natural Ligands For The Human Class I Histocompatibility Molecule HLA-A2, J. Med. Chem., **39**:2030-2039, (1996) * Günther, U.L., et al., "Solution Structures Of The DP IV (CD26) Inhibitor Val-BoroPro Determined By NMR Spectroscopy", Magnetic Resonance in Chem., 33:959-970, (1995) Gutheil, W.G., et al., "Separation Of L-PRO-DL-Boropro Into Its Component Diastereomers And Kinetic Analysis Of Their Inhibition Of Dipeptidyl Peptidase IV. A New Method For The Analysis Of Slow, Tight-Binding Inhibition", Biochemistry, 32:8723-8731, (1993) * Hall, et al., "Infimunogenetics of Dermatitis Herpetiformis", Seminars in Dermatology. **10**(3):240-245 (1991). * Hart, et al., "Design of Experimental Synthetic Peptide Immunogens for Prevention of HIV-1 and HTLV-/ Retroviral Infections", Pharmaceutical Biotechnology 6:821-845 (1995). *Hegen, M, et al. "Enzymatic Activity Of CD26 (Dipeptidylpeptidase IV) Is Not Required For Its Signalling Function In T Cells"/Immunobiology, 189:483/493, (1993) Hegen, M., et al. "Function Of Dipeptidylpeptidase IV (CD26, TP103) In Transfected Human T Cells", Cell Immunol., 146:249-260, (1993)

In re Application No. Form PTO-1449 U.S. Department of Commerce Atty. Docket: 2002941-0053 09/289,321 Patent and Trademark Office (REV. 8-83) **INFORMATION** Applicant: Bachovchin **DISCLOSURE STATEMENT** Filing Date: Group: (*Use several sheets if necessary*) April 9, 1999 1653 * Hegen, M., et al., "The T Cell Triggering Molecule Tp 103, J. Immunol., 144:2980-2914 (1990).* Heins, J., et al., "Mechanism of Proline-Specific Proteinases: (I) Substrate Specificity of Dipeptidyl Peptidase Peptidase IV From Pig Kidney and Proline-Specific Endopeptidase From Flavobacterium Meningosepticum", Biochemica Biophysica Acta, 954:161-169 (1988). * Ikagawa, et al., "Single Amino and Acid Substitutions on a Japanese Cedar Pollen Allergen Cry J-1) Derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism' L. Allergy & Clinical Immunol. 97 (1 Pt 1): 53-64 (1996). * James, et al., "Peptide Autoantigenicty of the Small Nuclear Ribonucleoprotein C" Clinical & Experimental Rheumatology, 13 (3):299-305 (1995). * Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", *Nature*, **368**:744-746, (1994). * Janeway, C., et al., "Immunobiology - The Immune System In Health And Disease", Current Biology LTD, Chapter 12, pp. 1-35, (1994). * Jardetzky, T.S., et al., "Three-Dimensional Structure Of A HumanClass II Histocompatibility Molecule Complexed With Superantigen, Nature, 368:711-718 (1994) * Jiang, et al., "Inhibition of Human Immunodeficiency Virus Type I Infection in a T-Cell Line (CEM) by New Dipeptidyl-Peptidase IV (CD26) Inhibitors", Res Viral, 148: 255-266, * Jorgensen, J.L., et al., "Molecular Components Of T-Cell Recognition," Annu. Rev. Immunol. 10:835-873 (1992). * Kalluri, et al., "Indentification of the Alpha 3 Chain of Type IV Collagen as the Common Autoantigen in Antibasement Membrane Disease and Goodpasture Syndrome", J. The American Society Of Nephrology 6 (4):1178-1185 (1995). * Kameoka, J., et al., "Direct Association Of Adenosine Deaminase With A T Cell Activation Antigen, CD26", Science, 261:466-469, (1993) * Kameoka, Jr., et al., Differential CD26-Mediated Activation Of The CD3 AND D2 Pathways After CD6-Depleted Allogeneic Bone Marrow Transplantation", Blood 85:1132-1137, (1995) * Karges, et al., 'Self and Non-Self Antigen in Diabetic Autoimmunity: Molecules and Mechanisms"/ Molecular Aspects Of Medicine 16(2):29-213 (1995). * Kelly, T.A., et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation Between Conformation And Activity", J. Am. Chem. Soc., 115:12637-12638, (1993) * Kelly, T.A., et al., "The Efficient Synthesis And Simple Resolution Of A Proline Boronate Ester Suitable For Enzyme Inhibition Studies", Tetrahedron 49:1009-1016 (1993). * Kettner, C.A. and Shen i, A.B., "Peptide Boronic Acid Inhibitors Of Trypsin-Like Proteases Their Preparation And Use As Anticoagulants And Inflammation Inhibitors", Chemical Abstracts, (1990), 112:80 (91790c). * Kettner, C.A., et al., "Kinetic Properties Of The Binding Of Alpha-Lytic Protease To Peptide Boronic Acids", Biochemistry, 27:7682-7688, (1988).

Atty. Docket: In re Application No. U.S. Department of Commerce Form PTO-1449 09/289,321 Patent and Trademark Office 2002941-0053 (REV. 8-83) **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) 1653 April 9, 1999 * Kinder, D., et al., "Analogues of Carbamyl Aspartate as Inhibitors..." J. Med. Chem., 33:819-823 (1990). * Kokowa, et al., "Detection of Platelet Antigen for Antiplatelet Antibodies in Idiopathic Thrombocytopenic Purpura by Flow Cytometry, Antigen-Capture ELISA, and Immunoblotting: A Comparative Study", Eur. J. Hematology 50 (2): 74-80 (1993) * Kubota, T., et al., "Diipepidyl peptidase IV (DP IV) Activity In Serum and On Lymymphocytes Of Mrl/Mp-Ipr/lpr Mice Correlates With Disease Onset", Clin. Exp. Immunol, 96:292-296. (1994). * Kubota, T., et al., "Involvement Of Dipeptidy Peptidase IV In An In Vivo Immune Response, Clin. Exp. Immunol., 89:192-197, (1992). * Kuchroo, V.K., et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated By A Diverse T Cell Repertoire", J. Immunol. 153:3326-3336 * Kuchroo, V.K., et al., "Cytokines And Adhesion Molecules Contribute To The Ability of Myelin Proteolipid Protein-Specific T Cell Clones To Mediate Experimental Allergic Encephalomyelitis", J. Immunol. 151:4371-4382 (1993). * Kuchroo, V.K., et al., "Experimental Allergic Encephalomyelitis Medicated By Cloned T Cells Specific For A Synthetic Peptide of Myelin Proteolipid Protein. Fine Specificity And T Cell Receptor V Beta Usage", J. Immunol. 148:3776-3782 (1992). * Kuchroo, V.K., et al., "Induction Of Experimental Allergic Encephalomyelitis By Myelin Proteolipid-Protein-Specific T Cell Clones and Synthetic Reptides", Pathobiology 59:305-312 * Kuchroo, V.K., et al, "T Cell Receptor (TCR) Usage Determines Disease Susceptibility In Experimental Autoin mune Encephalomyelitis: Studies with TCR VBeta *.2 Transgenic Mice", J. Experimental Medicine 179:1659-1664 (1994). * Kuchroo, V.K., et al., "T-cell Receptor Alpha Chain Plays a Critical Role in Antigen-Specific Suppressor Cell Function", Proc. Natl. Acad. Sci. USA 88:8700-8704 (1991). * Linington et al., "Cell Adhesion Molecules of the Immunoglobulin Supergene Family as Tissue-Specific Autoantigens: Induction of Experimental Allergic Meuritis (EAN) by PO Protein-Specific T Cell Lines", Eur. J. Immunol. 22 (7): 1813-1817 (1992). *Linsley, P.S., et al., "Effects of Anti-gp 120 Monocional Antibodies On CD4 Receptor Binding By The Env Protein Of Human Immunodeficiency Virus Type 1", J. Virology **62**:3695-3702 (1988). * Liu, et al., "Molecular Mapping of a Pathogenically Relevant BP180 Epitope Associated with Experimentally Induced Murine Bullous Pemphigoid" J. Immunol, 155 (11): 5449-5454 (1995). * Lopez, et al., "Characterization of SPf(60)n: A Chimeric Molecule Used as a Malaria Vaccine" Vaccine, 12 (7):585-591 (1994). Luftig, et al., "Update on Viral Pathogenesis", Recent Work on Three Human Pathogens Illustrates the Paths Being Taken in Viral Pathogenesis Research" ASM News, 56(7): 366-368, 1990.

In re Application No. U.S. Department of Commerce Atty. Docket: Form PTO-1449 Patent and Trademark Office 2002941-0053 09/289,321 (REV. 8-83) **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) April 9, 1999 1653 * Marguett, et al., "cDNA Cloning for Mouse Thymocyte-Activating Molecule", A Multifunctional Ecto-Dipeptidyl Peptidase IV (CD26) Included in a Subgroup of Serine Proteases", The Journal of Biological Chemistry, 267(4): 2200-2208, 1992. * Matteson, D., et al., "Synthesis And Properties Of Pinanediol a-Amido Boronic Esters" Organometallics, 3:1284-1288, (1984). * Mittrucker, H.W., et al. "The Cytoplasmic Tail Of The T Cell Receptor Zeta Chain is Required For Signaling Via CD26", Eur. J. Immunol., 25:295-297. (1995) * Morimoto, C., et al., 1F7 "A Novel Cell Surface Molecule, Involved in Helper Function Of CD4 cells". J. Immunol., 143:34030-3439 (1989) and published erratum appears in J. Immunology 144 (5):2027 (1990). * Mosmann, T.R., "Cytoking Patterns During The Progression To Aids", Science, 265:193-194, (1994). * Mullins, et al., "Transgenesis in the Rat and Larger Mammals" X Clinical Investigation 96 (1): 30-37 (1996). * Nardelli, et al., "A Chemically Defined Synthetic Vaccine Model for HIV-X", J. Immunol. **148** (3): 914-920/(1992). * Nicola, N, et al., "Guidebook To Cytokines And Their Receptors", Sambrook and Tooze Publication, Pp. 1-257, (1994) * O'Brien, et al., "An Immunogenetic Analysis of the T-Cell Recognition of the Major House Dust Mite Allergen Der p2: Identification of High- and Low-Responder HLA-DQ Alleles and Localization of T-Cell Epitopes" / Immunology 86 (2):176-182 (1995). * Panina-Bordignon, P., et al., "Universally Immunogenic T Cell Epitopes: Promiscuous Binding To Human MHC MHC Class II And Promiscuous Recognition By T Cells", Eur. J. *Immunol.* **19**:2237-2242 (1989). * Ostresh, et al., "Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries, Methods in Enzymology, 267: 220-234, 1996 * Perry, et al., "Autoreactive T Cell Specificity in Autoimmune Hemolytic Anemia of the NZB Mouse", Eur. J. Immunol. 26(1): 136-141/(1996). * Perstorp Biotec Company, "Molecular Biology Catalog", (1994) * Powers, C., et al., "Elastase Inhibitors Før Treatment Of Emphysema - NHLBI Workshop Summary" US Dept. of Health and Human Services, 1097-1100, (1985). * Protti, et al., "Myasthenia Gravis: Recognition of a Human Autoantigen at the Molecular Level" Immunol. Today 1/4 (7):363-368 (1993). Reinhold, D., et al., "Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor- 1 &TGF- 1) in stimulated mouse splenocytes and thymocytes" Immunology Letters , **58**:29-35, (1997). * Reynolds, et al., "T and B Epitope Determination and Analysis of Multiple Antigenic Peptides for the Schistosoma Mansoni Experimental Vaccine Triose-Phosphate Isomerase", J. Immunol.152 (1):193-200 (1994).

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321		
(REV. 8-83)	Patent and Trademark Office	2002941-0033	09/209,321		
	DRMATION OIPE	Applicant: Bachove	chin		
(Use seve	ral sheets if necessary	Filing Date: April 9, 1999	Group: 1653		
	* Rini, J.M., et al., "Crystal Structure Of A Hu Neutralizing Antibody, 50.1, In Complex With	man Immunodeficience Its V3 Loop Peptide	cy-Virus Type 1 Antigen Proc. Natl.	ı	
	Acad. Sci. USA\90:6325-9 (1993).	·			
1	* Ritu, et al., "Construction of Synthetic Immu	nogens: Use of 1- and	B-Cell Epitopes of CS 51-765/1992).	0	
1	* Scharpe, S., et al., "Purified And Cell-Bound Binding Profile, And Expression On F Cells Ir	and RESA Proteins of Plasmodium Falciparum' Vaccine 10 (11). 761-765 (1992). * Scharpe, S., et al., "Purified And Cell-Bound CD26: Enzymatic Inhibition, Antibody Binding Profile, And Expression On F Cells In Relation To Other Surface Markers", Verh. K.			
	Acad. Geneeskd. Belg., 56:537-559. (1994)		Tudiniductell I CV	1	
& L	Schmitz T., et al., "Potentiation Of The Immur Invest., 97:1545-1549, (1996).			L	
\times	* Schon, E., et al., "Dipeptidyl Peptidase IV in Role Of A Membrane Peptidase In The Immur 45 \\ 523-1328 (1986).	Human T Lymphoctyne System", Biomedica	res. An Approach To The a Biochimica Acta,	V	
X	* Schon, E., et al., Dipeptidyl Peptidase IV In The Immane System", Biol. Chem. Hoppe-Seyler, 372:305/311, (1991).				
	* Schön, E., et al., "Dipeptidyl Peptidase IV In	The Immune System	Effects of Specific		
	Enzyme Inhibitors On The Activity Of Dipeptidyl Peptidase IV And Proliferation Of Human Lymphocytes", <i>Biological Chemistry Hoppe Seyler</i> 372:305-311 (1991).			1	
$\overline{}$	* Schon, E., et ત્રી., "The Dipeptidyl Peptidase I	V, A Membrane Enzy	me Involved In The		
*	Proliferation Lymphocytes", <i>Biomedica Biochimica Acta</i> , 44 (1985). * Schön, E., et al., "The Role Of Dipeptidyl Peptidase IV In Human T Lymphocyte Activation. Inhibitors And Antibodies Against Dipeptidyl Peptidase IV Suppress Lymphocyte Proliferation And Immunoglobulin Synthesis In Vitro", <i>Eur. J. Immunol</i> . 17,1821-1826			C	
	(1987).		125 122 (1224)		
\longrightarrow	* Seed, B., "Making Agonists of Antagonists"	, Chemistry & Biology	7,1:125-129 (1994).		
\prec	* Shimojo, et al., "Identification of the Disease-Related T Cell Epitope of Ovalumin and Epitope-Targeted T Cell Inactivation in Egg Allergy" Int'l. Archives of Allergy & Immunol.			1	
X	* Snow, R.J., et al., "Studies On Proline Boronic Acid Dipeptide Inhibitors Of Dipeptidyl Peptidase IV: Identification Of A Cyclic Species Containing A B-N Bond", J. Am. Chem.				
	Soc., 116:10860-10869, (1994). * Songyang, Z., et al., "SH2 Domains Recogning 72:767-7/18, (1993)	ze Specific Phosphop	eptide Sequences", Cell,	-	
*	* Subramanyam, M., et al, "CD26, AT-Cell A Specific Immune-Suppression By Inactivation Dipeptidyl Peptidase IV (CD26) in Metabolism 162, (1995)	OF CD26: A Clue To	The Aids Paraxox?", in	c	
Dil	* Subramanyam, M., et al., "Mechanism Of H. T Cell Responsiveness", J. Immunol., 150:254		ition Of Antigen-Specific		
Di	Subramanyam, W.G., et al., "Mechanism of H Specific T Cell Responsiveness", J. Immunol.	IV-1 Tat Induced Inhi			

ï

Form PTO-1449 U.S. Department of Commerce Atty. Docket: In re Application No. 09/289,321 (REV. 8-83) Patent and Trademark Office 2002941-0053 **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) April 9, 1999 1653 * Sudmeier, J.L., et al., "Solution Structures Of Active And Inactive Forms Of The DP IV (CD26) Inhibitor Pro-Boropro Determined By Nmr Spectroscopy", Biochemistry, 33:12427-12438, (1994). * Tam, J.P., "Synthetic Peptide Vaccine Design: Synthesis And ProperitiesOf A High-Density Multiple Antigenic Peptide System", Proc. Natl. Acad. Sci. USA, 85:5409-5413, * Tanaka, T., et al. "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", J. Immyhol., 149:481-486. (1992) * Tanaka, T. et al., "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", J. Immunol. 149/481-486 (1992); published erratum appears in J. Immunol. **50**(5):20**9**0 (1993). * Tanaka, T., et al., The Costimulatory Activity of The CD26 Antigen Requires Dipeptidyl Peptidase IV Enzaymatic Activity", Proc. Natl. Acad. Sci. USA, 90:4586-4590. (1993) * Thompson, R., "Use Of Peptide Aldehydes To Generate Transition-State Analogs Of Elastase", Biochemistry, 12:1:47-51 (1973). Thompson, R. "Pentide Aldehydes, Potent Inhibitors of Serine and Cysteine Proteases", 19: 2**3**0-225. * Uibo, et al., "Characterization of Adrenal Autoantigens Recognized by Sera From Patients with Autoimmune Polyglandular Syndrome (APS) Type V. (J. Autoimmunity 7/3): 399,411 (1994)* Van Noort, et al., "The Small Heat-Shock Protein Alpha B-Crystallin as Candidate Autoantigen in Multiple Scherosis" Nature 375 (6534):798-801 (, 2995). * Watson, J.D., "Continuous Proliferation of Murine Antigen Specific Helper T Lymphocytes in Culture", J. Experimental Medicine 150:15 NO (1979). * Welch, J.T., and Lin J., "Fluoroolean Containing Dipetide Isoteres As Inhibitors Of Dipeptidyl Peptidase IV (CD26), Tetrahedron, 52:291, 304, (1995). * Wijdenes, et al, "Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which Use the gp130 For Signal Transduction", Abstract. * Wyss-Coray, T., et al., "Use/Of Antibody/Peptides Constructs Of Direct Antigenic Peptides To T Cells: Evidence For T Cells Processing And Presentation", Cellular Immixtol., 139 (1):268-73 (1992). *Yoshimoto, T., et al., "Comparison Of Inhibitory Effects Of Prolinal-Containing peptide Derivates On Prolyl...", (1985) J. Biochem., 98:975-979, (1985) * Zhu, X., et al., "T Cell Epitope Mapping of Ragweed Pollen Allergen Ambrosia Artemisiifolia (Amb a 5) and Ambrosia Trifida (Amb t 5) and the Role of Free Sulfhydryl Groups in T Cell Recognition" J. Immunol. 155 (10):5064-5073 (1995). * Zimmerman, D.H., et al. "A New Approach To T-Cell Activation: Natural And Synthetic Conjugates Capable Of Activating T Cells", Vaccine Res., 5:91-102, (1996). Zimmerman, D.H., et al., "Immunication With Peptide Heteroconjugates Primes A T Helper Cell..." Vacqine Res. 5:103-118, (1996).

Form PTO-1449 (REV. 8-83)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053

In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

NOV 0 2 2000

Applicant: Bachovchin

Filing Date: April 9, 1999 Group: 1653

EXAMINER

Laurd Latter

DATE CONSIDERED 8/28 0

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3184391_1.DOC